Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

01 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

07 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

05 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

01 Jun 2024 08:15:00 By Nasdaq GlobeNewswire

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

01 Jun 2024 08:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

07 May 2024 16:05:01 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

26 Apr 2024 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Present at 2024 ASCO Annual Meeting

25 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

14 Mar 2024 09:05:00 By Nasdaq GlobeNewswire

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

04 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024

16 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index

13 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

13 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023

31 Oct 2023 07:05:00 By Nasdaq GlobeNewswire

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

18 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA

17 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication in Cancers

16 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology

21 Sep 2023 16:05:00 By Nasdaq GlobeNewswire